ITUS Corp. | Cash Flow

Fiscal year is November-October. All values USD Thousands.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
10,080.10
9,606.30
1,379.00
5,016.40
5,009.00
Depreciation, Depletion & Amortization
-
314.50
325.30
358.60
368.50
Other Funds
-
200.00
-
-
-
Funds from Operations
3,782.60
1,392.30
2,245.00
3,221.10
4,205.00
Changes in Working Capital
595.80
987.00
881.70
160.60
408.20
Net Operating Cash Flow
3,186.80
2,379.30
1,363.40
3,381.70
3,796.70
Capital Expenditures
-
-
54.80
146.50
30.20
Sale of Fixed Assets & Businesses
-
-
-
-
45.00
Purchase/Sale of Investments
500.00
2,500.00
100.00
1,650.00
2,750.00
Net Investing Cash Flow
499.30
2,506.70
45.20
1,503.50
2,735.20
Issuance/Reduction of Debt, Net
-
3,500.00
-
-
3,000.00
Net Financing Cash Flow
3,246.00
7,349.00
400.60
2.70
7,382.90
Net Change in Cash
558.50
2,463.10
1,008.00
1,880.90
851.10
Free Cash Flow
3,186.80
2,379.30
1,308.60
3,528.20
3,826.90
Change in Capital Stock
3,246.00
4,049.00
400.60
33.60
10,382.90
Other Uses
0.70
6.70
-
-
-

About ITUS

View Profile
Address
3150 Almaden Expressway
San Jose California 95118
United States
Employees -
Website http://www.ituscorp.com
Updated 09/14/2018
ITUS Corp. engages in the development, acquisition and licensing emerging technology in the field of biotechnology. It focuses on platform called Cchek, a series of inexpensive non-invasive blood tests for the early detection of cancer, which is based on the body's immunological response to the presence of a malignancy. The company was founded on November 5, 1982 and is headquartered San Jose, CA.